Observational Study on Survival, Quality of Life, and Surgery Outcomes in Locally Advanced and Borderline Resectable Pancreatic Cancer

What this Trial Is About

Researchers are observing patients with borderline resectable and locally advanced pancreatic cancer to assess overall survival, quality of life, and surgical removal rates. The study includes patients treated at Nordic hospitals, focusing on those with non-endocrine pancreatic cancer as defined by established clinical guidelines. The goal is to understand outcomes in real-world treatment settings without altering care. The study is observational and does not involve any experimental treatment. Participants are identified through regional tumor boards and followed to track their treatment compliance, response to chemotherapy, and quality of life at multiple time points ranging from initial inclusion up to 24 months. Researchers will also evaluate factors predicting the possibility of surgical removal of the tumor. During the study, participants will have their quality of life assessed at baseline and at 3, 6, 9, 12, and 24 months after enrollment. Outcomes like median overall survival and surgical resection rates will be monitored for up to 72 months or until death. The study involves collecting clinical data and patient-reported information over several years to gain insights into the disease course and treatment impact.

Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer